irritABILITY
Think it’s PMS? Think again.
It could be PMDD.
Fluoxetine (trade name Prozac) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine is approved for the treatment of major depression (including pediatric depression), obsessive-compulsive disorder (in both adult and pediatric populations), bulimia nervosa, anorexia nervosa, panic disorder and premenstrual dysphoric disorder. Despite the availability of newer agents, it remains extremely popular. Over 22.2 million prescriptions for generic formulations of fluoxetine were filled in the United States in 2007, making it the third most prescribed antidepressant.
Eli Lilly’s patent on Prozac (fluoxetine) expired in August, 2001, prompting an influx of generic drugs onto the market. Prozac was rebranded “Sarafem” for the treatment PMDD in an attempt to stem the post-patent decrease in Eli Lilly’s sales of fluoxetine.
Brand name: Sarafem
Generic name/category: Fluoxetine, selective serotonin reuptake inhibitor (SSRI)
Company: Lilly
Country/Market: USA, North America
Indication(s)/use: Premenstrual Dysphoric Disorder (PMDD)
Target: Consumers (DTC)
Tagline: More like the woman you are
Medium: Print ad
Size/duration: single-page
Publication/Aired: Ebony – February 2001
Tags: bulimia-nervosa, english, lilly, north america, print ad, print advertising, sales, wikipedia, yellow
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice